
SEALSQ Expands Its Quantum-Safe Strategy with SEALQUANTUM.com Initiative and a Up To $20 Million Investments in Quantum & AI Startups
To date, two investments have already been announced while two more are currently in advanced stage of negotiations with a targeted announce date of before the end of Q2. Recent announcements include:
Investment in ColibriTD, a quantum computing company focused on delivering end-to-end quantum solutions that seamlessly integrate with classical computing infrastructure. The investment aims to integrate ColibriTD's quantum-as-a-service platform into SEALSQ's Quantum Roadmap and make quantum computing accessible to industries seeking cutting-edge solutions for real-world challenges.
Exclusive negotiations to acquire IC'ALPS SAS ('IC'ALPS'), an ASIC design and supply specialist based in Grenoble, France. IC'ALPS via its two design centers in Grenoble and Toulouse, provides customers with a complete offering for Application Specific Integrated Circuits (ASIC) and Systems on Chip (SoC) development from circuit specification. Via this investment, SEALSQ aims to reinforce its commitment in advancing its ASIC development to meet the growing demand.
SEALSQ's initiative complements multiple projects initiated by Europe's top technology founders as part of a new scheme designed to help build the next generation of European €100 billion companies. By fostering the development of quantum-safe and AI-powered solutions, SEALSQ aims to strengthen Europe's position as a global technology leader while addressing critical cybersecurity, AI, and semiconductor challenges.
While SEALQUANTUM is a global investment initiative, SEALSQ is particularly committed to supporting Europe's technological ecosystem, recognizing the urgent need to boost European technology capabilities amid rising geopolitical tensions and increasing global competition. The rapid evolution of AI and quantum technologies is reshaping industries at an unprecedented pace, and SEALSQ sees an opportunity to accelerate its AI-quantum roadmap by investing in breakthrough European innovations.
SEALQUANTUM is a core pillar of the SEALSQ Quantum Roadmap, a strategic initiative designed to provide end-to-end quantum-safe solutions while ensuring cryptographic agility in an evolving digital landscape. This investment will support startups at the forefront of:
Quantum security and computing architectures
Quantum networking solutions
AI-powered chipsets that integrate with post-quantum semiconductors
AI cloud-based quantum services hardened by SEALSQ's security protocols
By focusing on quantum-resilient AI and semiconductor technologies, SEALSQ is driving the development of next-generation solutions capable of safeguarding critical infrastructure, financial systems, and government institutions from the emerging threats of quantum computing.
Supporting European Entrepreneurs in AI, Cybersecurity, Quantum, and Space
Beyond quantum computing and AI, SEALSQ is also investing in young European entrepreneurs working on cybersecurity, quantum sectors, and space technology to complement the WISeSat satellite constellation. These investments align with broader European initiatives to strengthen the continent's strategic autonomy in key technology sectors.
Carlos Moreira, CEO of SEALSQ, emphasized: 'By investing in cutting-edge startups focused on quantum computing, QaaS, and AI-driven semiconductor technologies, we are fostering innovation, promoting unconventional thinking, and assisting entrepreneurs in finding creative solutions to complex challenges. Innovation and our commitment to creating a better world have always been at the core of our mission, and we are proud to continue this tradition by investing up to $20 million of our available cash through SEALQUANTUM.'
Building a Quantum-Resilient Future
Through SEALQUANTUM, SEALSQ is reinforcing its commitment to building a quantum-resilient world, ensuring that trust, privacy, and compliance remain foundational principles in an increasingly complex cyber landscape. As the quantum era approaches, SEALSQ is taking proactive steps to secure the future of digital infrastructure, enabling industries and governments to navigate the transition to a quantum-safe ecosystem.
For more details, visit: SEALSQ SEALQUANTUM Initiative.
About SEALSQ:
SEALSQ is a leading innovator in Post-Quantum Technology hardware and software solutions. Our technology seamlessly integrates Semiconductors, PKI (Public Key Infrastructure), and Provisioning Services, with a strategic emphasis on developing state-of-the-art Quantum Resistant Cryptography and Semiconductors designed to address the urgent security challenges posed by quantum computing. As quantum computers advance, traditional cryptographic methods like RSA and Elliptic Curve Cryptography (ECC) are increasingly vulnerable.
SEALSQ is pioneering the development of Post-Quantum Semiconductors that provide robust, future-proof protection for sensitive data across a wide range of applications, including Multi-Factor Authentication tokens, Smart Energy, Medical and Healthcare Systems, Defense, IT Network Infrastructure, Automotive, and Industrial Automation and Control Systems. By embedding Post-Quantum Cryptography into our semiconductor solutions, SEALSQ ensures that organizations stay protected against quantum threats. Our products are engineered to safeguard critical systems, enhancing resilience and security across diverse industries.
For more information on our Post-Quantum Semiconductors and security solutions, please visit www.sealsq.com.
Forward-Looking Statements
This communication expressly or implicitly contains certain forward-looking statements concerning SEALSQ Corp and its businesses. Forward-looking statements include statements regarding our business strategy, financial performance, results of operations, market data, events or developments that we expect or anticipate will occur in the future, as well as any other statements which are not historical facts. Although we believe that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates which are inherently subject to significant uncertainties and contingencies, many of which are beyond our control. Actual results may differ materially from those expressed or implied by such forward-looking statements. Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include SEALSQ's ability to continue beneficial transactions with material parties, including a limited number of significant customers; market demand and semiconductor industry conditions; and the risks discussed in SEALSQ's filings with the SEC. Risks and uncertainties are further described in reports filed by SEALSQ with the SEC.
SEALSQ Corp is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Morgan Stanley Lifts PT on CG Oncology (CGON) to $56, Keeps an Overweight Rating
CG Oncology, Inc. (NASDAQ:CGON) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 17, Morgan Stanley raised the firm's price target on CG Oncology, Inc. (NASDAQ:CGON) to $56 from $52, while maintaining an Overweight rating on the shares. A researcher in a laboratory examining a vial of oncolytic herpes simplex virus, demonstrating the company's commitment to finding a cure for cancer. The firm told investors in a research note that although the non-muscle invasive bladder cancer space has undergone recent and anticipated approvals, the space is comprehensive enough to accommodate multiple players. It thus considers cretostimogene to be meaningfully differentiated by its safety data and durability, along with having 'best-in-disease potential' that supports an optimistic rating for the company. CG Oncology, Inc. (NASDAQ:CGON) is a clinical biopharmaceutical company that develops and commercializes bladder-sparing therapeutics for bladder cancer. Its product cretostimogene is initially in clinical development for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). While we acknowledge the potential of CGON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
37 minutes ago
- Yahoo
Should You Buy This AI Stock That Soared 800% Last Year and Has a $140 Billion Total Addressable Market?
This company has reported accelerating revenue growth in recent quarters, and in the latest period, revenue soared more than 150%. After great gains last year, the stock slipped 45% in the first half of this year. 10 stocks we like better than SoundHound AI › Last year was a big one for artificial intelligence (AI) stocks, with companies in the sector leading all three major benchmarks to gains. Though the momentum halted temporarily earlier this year, as investors worried about the impact of import tariffs on the economy, this positive energy has returned. Investors are optimistic that trade talks will result in lower-than-expected tariffs, limiting the negative effects on companies, and that has buoyed interest in growth players, including AI stocks. Some AI stocks, though, have yet to feel the rebound. Considering the long-term AI growth story hasn't changed, these players may offer you bargain buying opportunities today. Let's consider one in particular. This AI stock surged more than 800% in 2024 but dropped 45% in the first half of this year. Meanwhile, it's a specialist in its field, one with a total addressable market of more than $140 billion. Is this player a buy right now? The AI stock I'm talking about is SoundHound AI (NASDAQ: SOUN), a company with expertise in voice AI, reinforced by more than 190 granted patents. Though other companies, even big players such as Amazon or Microsoft, are involved in the field, SoundHound stands out thanks to its speech-to-meaning technology. The company translates speech directly to meaning, bypassing the common step of translating speech to text first, therefore gaining in speed and quality. Customers clearly like SoundHound's offerings, as revenue has taken off, and the company has signed deals across industries. This is a key point because, in its earlier days, SoundHound primarily served the automobile industry. This strength in fields such as healthcare, retail, travel, and more, as well as the fact that no customer represents more than 10% of revenue, greatly reduces SoundHound's risk. That's because if one customer or industry cuts spending, others may compensate. SoundHound's revenue in the recent quarter advanced 151% to about $29 million, which is great. But what's even better is that the company still has plenty of room for growth, considering its current revenue level and the total addressable market of $140 billion, which spans 14 different industries. And the company has three ways to generate revenue: through royalties on its products, subscriptions for services, and taking additional revenue from the use of its products and services. Of course, despite SoundHound's expertise in the field, the company still faces the risk of major rivals, such as those mentioned above, gaining market share due to their immense resources. That's what makes SoundHound a stock that carries some risk right now, and even though the stock has slipped this year, the decline looks small compared to the gain posted last year. These factors could limit SoundHound's growth in the near term. Still, the company has seen growth accelerate in recent quarters, from 89% in the third quarter of last year to 101% in the fourth quarter and even higher in the most recent period. Further, as mentioned above, SoundHound may still be in its early stages of growth. So, what does this mean for you as an investor? Should you buy SoundHound now on the dip? The answer depends on your investment strategy. If you're a cautious investor, you're probably better off buying a larger, well-established player, such as Amazon or Microsoft, that may benefit from voice AI but also from broader, profitable businesses. Over time, they've proven their earnings and stock performance strengths. If you're an aggressive investor, though, SoundHound looks like a fantastic AI buy right now. The stock has slipped from its high, offering you a lower entry point. Revenue has clearly accelerated in recent quarters, and the company has successfully broadened its customer base across industries. On top of that, I like that SoundHound is financially healthy, with no debt and $246 million in cash. All this makes it a great AI stock to get in on right now and hang on to as its growth story develops. Before you buy stock in SoundHound AI, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and SoundHound AI wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Adria Cimino has positions in Amazon. The Motley Fool has positions in and recommends Amazon and Microsoft. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Should You Buy This AI Stock That Soared 800% Last Year and Has a $140 Billion Total Addressable Market? was originally published by The Motley Fool
Yahoo
an hour ago
- Yahoo
Alvotech (ALVO) Announces a Commercialization Agreement With Advanz Pharma
Alvotech (NASDAQ:ALVO) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 1, Alvotech (NASDAQ:ALVO) and Advanz Pharma announced a commercialization agreement to distribute and supply AVT10, a biosimilar candidate to Cimzia, in Europe. A scientist in a laboratory working on drug research. The agreement is expected to support Alvotech's (NASDAQ:ALVO) strategic position in the biosimilar market while allowing increased access to high-quality biologics in Europe. This could potentially affect the market share of the current treatments in the chronic rheumatic diseases sector. Alvotech (NASDAQ:ALVO) is a biotechnology company that develops and manufactures biosimilar medicines. Headquartered in Luxembourg, the company operates in the following geographical segments: Europe, North America, Asia, and Other. While we acknowledge the potential of ALVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.